Tazemetostat
About
Therapy type: Targeted therapy
Therapy strategy: EZH2 inhibition
Mappings
NCI Thesaurus: Tazemetostat (coding:ncit:C107506)
RxNorm: tazemetostat (coding:rxcui:2274378, coding:omop:37498602)
SNOMED: Tazemetostat (coding:sctid:840405005, coding:omop:3666985)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (1) | EZH2 p.Y646N | Follicular Lymphoma | Tazemetostat | |
| FDA (1) | EZH2 p.Y646F | Follicular Lymphoma | Tazemetostat | |
| FDA (1) | EZH2 p.Y646H | Follicular Lymphoma | Tazemetostat | |
| FDA (1) | EZH2 p.Y646S | Follicular Lymphoma | Tazemetostat | |
| FDA (1) | EZH2 p.Y646C | Follicular Lymphoma | Tazemetostat | |
| FDA (1) | EZH2 p.A682G | Follicular Lymphoma | Tazemetostat | |
| FDA (1) | EZH2 p.A692V | Follicular Lymphoma | Tazemetostat |